Katie Rivera Email & Phone Number

Philadelphia, Pa, Us

TECVAYLI (first-in-class, T-cell redirecting, BCMA bispecific antibody for multiple myeloma) - Director of Global Commercial Strategy:- Responsible for strategy development and launch readiness for teclistamab in Multiple Myeloma partnering across functional partners including Global Medical Affairs, R&D, Global Market Access and the J&J Regional teams to develop and execute commercial strategies, tactics, and messaging in support of the launch and future pipeline indications.

DARZALEX (first-in-class, CD38-targeted monoclonal antibody (mAb)) for Multiple Myeloma – US Market Access Professional:- Market Access launch leader for DARZALEX FASPRO- Responsible for developing and executing market access marketing strategies for inline and pipeline indications. - Ensure payer coverage, reimbursement and key account access by developing integrated strategies across channels including MCOs, IDNs, GPOs, and 3rd Party Pathways. - Lead strategic alignment with sales and Market Access field leadership and effectively establish long-range strategy, communication, and execution plans with prioritized stakeholders

IMBRUVICA (first-in-class BTK inhibitor for Leukemia and Lymphoma) US Marketing professional: - Responsible for driving growth for IMBRUVICA by leading marketing strategy and execution for chronic lymphocytic leukemia (CLL) with an alliance partner- New indication launch leader- Responsible for HCP non-personal, media and digital strategy for IMBRUVICA

Melbourne, Victoria, Au

Led development and execution of US marketing strategies and tactical plans for a first to market blood coagulation factor replacement product (Kcentra).

Brentford, Middlesex, Gb

Led the development of insight-driven, integrated multi-channel marketing campaigns that consistently communicated the core clinical value proposition to key customer segments for a kinase inhibitor (VOTRIENT) for advanced renal cell carcinoma and advanced soft tissue sarcoma.

Brentford, Middlesex, Gb

Led strategy and development of professional and patient marketing materials supporting the US launch of a BRAF inhibitor (TAFINLAR) and MEK inhibitor (MEKINIST) for metastatic melanoma.

Brentford, Middlesex, Gb

Global and US Launch Project Management leader to drive successful launches of a BRAF inhibitor (TAFINLAR) and MEK inhibitor (MEKINIST) as single and combination agents for metastatic melanoma and a thrombopoietin receptor agonist (PROMACTA) for use in Hepatitis C Related Thrombocytopenia.

Dublin 2, Ie

Health & Life Sciences Practice, Customer Relationship Management / Marketing Operations Specialty.Strategic consulting partner across various projects at leading Pharmaceutical companies including AstraZeneca, Wyeth, Pfizer, and GlaxoSmithKline. Areas of focus included: Customer Relationship Management, Organizational Strategy, Merger Integration, Multi-Channel Marketing, Customer Experience Strategy, Change Management, and Commercial Model Transformation.

New Brunswick, Nj, Us

Ortho McNeil Pharmaceuticals, Pharmaceutical Supply Group of Americas (PSGA), External Manufacturing Co-op

B.S. Business Management, International Business & International Studies

Commericial Leadership Excellence Program

Emerging Leaders Development Progam

Spanish